FOXP3-targeted immune therapy for IPEX
Part of Immune system & allergy clinical trials.
This Phase 1 study tests a gene-targeted immune treatment designed for people with IPEX caused by a FOXP3 gene change. It aims to improve immune control in people whose IPEX symptoms are not well controlled or who cannot safely take standard immune-suppressing medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a FOXP3 gene mutation confirmed
- You should have IPEX with ongoing or worsening symptoms, and you either can’t use immune-suppressing medicine or have symptoms that come back
- If you have had a prior stem cell transplant, your IPEX symptoms have returned and still need immune-suppressing treatment
- You must be able to tolerate the study procedure (including blood collection/leukapheresis if needed) and meet weight and overall health thresholds
- You must not have an active ongoing infection and should have acceptable heart, liver, kidney, and bone marrow function
- You must be able to give consent (or have a legally authorized caregiver consent for a child)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a tool (a way of collecting health information) to help doctors make better diagnosis, prognosis, and treatment decisions for children with certain immune problems. It also includes healthy children (like relatives) as comparison groups, to see how well the tool works.
This trial tests a gene therapy that adds a working FOXP3 gene to your own T cells to help them regulate your immune system. It's for people with IPEX syndrome whose disease is not controlled by standard treatments or who cannot have a stem cell transplant.
This trial tests an experimental injection called Ixovex-1, either alone or with another drug (pembrolizumab), for people with advanced solid tumors that can be injected. It is for those who have run out of standard options and have tumors that are not too deep inside the body.
This trial tests a new mRNA-based treatment for people with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The treatment aims to lower the immune attack and raise platelet counts.
This Phase 1 trial studies a new cancer medicine (IBI343) that targets certain tumor cells to see how safe it is and how well it may work. You may be eligible if you have advanced, hard-to-remove cancers and your tumor has a specific marker called CLDN18.2.
This trial tests a treatment to reduce certain antibodies in the blood that may be making your idiopathic pulmonary fibrosis (IPF) worse. The goal is to slow down the progression of the disease and help you breathe easier.
Hear when a new IPEX trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.